18994-90-6

Basic information

• Product Name: 1-(4-Nitrobenzyl)-1H-imidazole
• Synonyms: 1-(4-NITROBENZYL)-1H-IMIDAZOLE;1-(4-Nitrobenzyl)imidazole;1-(4-Nitrobenzyl)-1H;1-[(4-nitrophenyl)Methyl]-1H-iMidazole;1-[(4-nitrophenyl)methyl]imidazole;Imidazole, 1-(4-nitrobenzyl)-
• CAS NO: 18994-90-6
• Molecular Formula: C₁₀H₉N₃O₂
• Molecular Weight: 203.2
• EINECS: 604-604-1
• Mol File: 18994-90-6.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 418.5 °C at 760 mmHg
• Flash Point: 206.9 °C
• Appearance: /
• Density: 1.29 g/cm³
• CAS DataBase Reference: 1-(4-Nitrobenzyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Nitrobenzyl)-1H-imidazole(18994-90-6)
• EPA Substance Registry System: 1-(4-Nitrobenzyl)-1H-imidazole(18994-90-6)

Safety Data

• Hazardous Substances Data: 18994-90-6(Hazardous Substances Data)

Usage

General Description

1-(4-Nitrobenzyl)-1H-imidazole is a chemical compound with the molecular formula C10H9N3O2. It is an imidazole derivative that contains a nitrobenzyl group. 1-(4-Nitrobenzyl)-1H-imidazole is often used in the synthesis of pharmaceuticals and agrochemicals. The nitro group in its structure makes it a potential candidate for various biological activities. It is mainly used as a building block in the pharmaceutical industry for the synthesis of potentially active compounds. Additionally, it has also shown potential as an antibacterial and antifungal agent in some studies.

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 4238-71-5 1-benzylimidazole 
• 619-73-8 4-nitrobenzyl chloride 
• 530-62-1 1,1'-carbonyldiimidazole 
• 288-32-4 1H-imidazole 
• 100-14-1 4-nitrobenzyl chloride 

Downstream Products

• 1292315-74-2 5-[2-[[4-(imidazol-1-ylmethyl)phenyl]amino]pyrimidin-4-yl]-2-tetrahydropyran-4-yloxy-benzonitrile 
• 56643-86-8 4-(2-Methylimidazol-1-ylmethyl)nitrobenzene 
• 125665-47-6 N-(4-Imidazol-1-ylmethyl-phenyl)-phthalamic acid 
• 759428-67-6 (4-imidazol-1-ylmethyl-phenyl)-hydrazine 
• 56643-85-7 4-(1-imidazolylmethyl)aniline 
• 102432-62-2 (4-Imidazol-1-ylmethyl-phenyl)-[1-(3,4,5-trimethoxy-phenyl)-meth-(E)-ylidene]-amine 
• 102432-64-4 N-(4-{[(E)-4-Imidazol-1-ylmethyl-phenylimino]-methyl}-phenyl)-acetamide 

Relevant articles and documents

Antifungal activity of 1,4-dialkoxynaphthalen-2-acyl imidazolium salts by inducing apoptosis of pathogenic candida spp.

Even though Candida spp. are staying commonly on human skin, it is also an opportunistic pathogenic fungus that can cause candidiasis. The emergence of resistant Candida strains and the toxicity of antifungal agents have encouraged the development of new classes of potent antifungal agents. Novel naphthalen-2-acyl imidazolium salts (NAIMSs), especially 1,4-dialkoxy-NAIMS from 1,4-dihydroxynaphthalene, were prepared and evaluated for antifungal activity. Those derivatives showed prominent anti-Candida activity with a minimum inhibitory concentration (MIC) of 3.125 to 6.26 μg/mL in 24 h based on microdilution antifungal susceptibility test. Among the tested com-pounds, NAIMS 7c showed strongest antifungal activity with 3.125 μg/mL MIC value compared with miconazole which showed 12.5 μg/mL MIC value against Candida spp., and more importantly >100 μg/mL MIC value against C. auris. The production of reactive oxygen species (ROS) was increased and JC-1 staining showed the loss of mitochondrial membrane potential in C. albicans by treatment with NAIMS 7c. The increased release of ultraviolet (UV) absorbing materials suggested that NAIMS 7c could cause cell busting. The expression of apoptosis-related genes was induced in C. albicans by NAIMS 7c treatment. Taken together, the synthetic NAIMSs are of high interest as novel antifungal agents given further in vivo examination.

Synthesis and investigation of inhibitory activities of imidazole derivatives against the metallo-β-lactamase IMP-1

Mutations in bacteria can result in antibiotic resistance due to the overuse or abuse of β-lactam antibiotics. One strategy which bacteria can become resistance toward antibiotics is secreting of metallo β-lactamase enzymes that can open the lactam ring of the β-lactam antibiotic and inactivate them. This issue is a threat for human health and one strategy to overcome this situation is co-administration of β-lactam antibiotics with an inhibitor. So far, no clinically available inhibitors of metallo β-lactamases (MBLs) reported and the clinically inhibitors of serine β-lactamase are useless for MBLs. Accordingly, finding a potent inhibitor of the MBLs being very important. In this study, imidazole derivatives primarily were synthesized and their inhibitory activity were measured. Later in silico binding model was used to predict the configuration and conformation of the ligands into the active site of enzyme. Two molecules demonstrated with IC50 of 39 μM and 46 μM against MBL (IMP-1).

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.